This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

Amgen will fully test out this staggered dosing strategy in its Phase III 72-week-long trial of MariTide for people with obesity and Type 2 diabetes, which has already begun enrollment.

Guggenheim analyst Vamil Divan maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $288.00. The company’s shares closed yesterday at ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP-1 drugs, it targets a hormone that slows stomach emptying. Over 12 weeks, ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.